 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || leramistat (MBS2320) / Istesso, J&J, Rinvoq (upadacitinib) / AbbVie
Enrollment change, Trial primary completion date: Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects (clinicaltrials.gov) - Jul 28, 2024
P1, N=48, Recruiting, Sponsor: Modern Biosciences Ltd
N=36 --> 48 | Trial primary completion date: May 2024 --> Sep 2024
- || leramistat (MBS2320) / Istesso, J&J, Rinvoq (upadacitinib) / AbbVie
Enrollment open: Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects (clinicaltrials.gov) - May 7, 2024
P1, N=36, Recruiting, Sponsor: Modern Biosciences Ltd
N=36 --> 48 | Trial primary completion date: May 2024 --> Sep 2024 Not yet recruiting --> Recruiting
- || leramistat (MBS2320) / Istesso, J&J, Rinvoq (upadacitinib) / AbbVie
New P1 trial: Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects (clinicaltrials.gov) - Apr 23, 2024
P1, N=36, Not yet recruiting, Sponsor: Modern Biosciences Ltd
- |||| leramistat (MBS2320) / Istesso, J&J
Trial completion: Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA (clinicaltrials.gov) - Feb 5, 2024
P2, N=249, Completed, Sponsor: Modern Biosciences Ltd
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | leramistat (MBS2320) / Istesso, J&J
Phase classification: Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA (clinicaltrials.gov) - Jan 11, 2024
P2, N=249, Active, not recruiting, Sponsor: Modern Biosciences Ltd
Active, not recruiting --> Completed Phase classification: P2b --> P2
- || leramistat (MBS2320) / Istesso, J&J
Trial completion date, Trial primary completion date: A Study to Investigate Leramistat in Patients With IPF (clinicaltrials.gov) - Jan 1, 2024
P2, N=150, Recruiting, Sponsor: Modern Biosciences Ltd
- ||| leramistat (MBS2320) / Istesso, J&J
Enrollment closed: Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA (clinicaltrials.gov) - Nov 9, 2023
P2b, N=249, Active, not recruiting, Sponsor: Modern Biosciences Ltd
Phase classification: P2b --> P2 Recruiting --> Active, not recruiting
- ||| leramistat (MBS2320) / Istesso, J&J
Enrollment open: A Study to Investigate Leramistat in Patients With IPF (clinicaltrials.gov) - Sep 11, 2023
P2, N=150, Recruiting, Sponsor: Modern Biosciences Ltd
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| leramistat (MBS2320) / Istesso, J&J
New P2 trial: A Study to Investigate Leramistat in Patients With IPF (clinicaltrials.gov) - Jul 20, 2023
P2, N=150, Not yet recruiting, Sponsor: Modern Biosciences Ltd
- |||| leramistat (MBS2320) / Istesso, J&J
Enrollment open: Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA (clinicaltrials.gov) - Oct 31, 2022
P2b, N=224, Recruiting, Sponsor: Modern Biosciences Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| leramistat (MBS2320) / Istesso, J&J
New P2b trial: Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA (clinicaltrials.gov) - Jul 15, 2022
P2b, N=224, Not yet recruiting, Sponsor: Modern Biosciences Ltd
- || MBS2320 / Istesso
Rheumatologe: MBS2320 at the EULAR 2020 Online Meeting https://t.co/jLo1QtrMiw #RA #rheumatoidarthritis #eular2020 #eular2020goesvirtual (Twitter) - Jul 1, 2020
- MBS2320 / Istesso
[VIRTUAL] MBS2320, A NOVEL SELECTIVE MODULATOR OF IMMUNE METABOLISM, IN PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS: SAFETY, TOLERABILITY AND EFFICACY RESULTS OF A PHASE 2 STUDY (Wollheim) - Mar 4, 2020 - Abstract #EULAR2020EULAR_229;
Nausea was the most common TEAE, was generally mild in severity and resolved without treatment. In this population of patients with hard-to-treat, severe, active, erosive disease MBS2320 showed evidence of a clinical benefit on both ACR20 responses and DAS28-CRP.
- | leramistat (MBS2320) / Istesso, J&J
Trial completion: Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Aug 14, 2019
P2a, N=121, Completed, Sponsor: Modern Biosciences plc
In this population of patients with hard-to-treat, severe, active, erosive disease MBS2320 showed evidence of a clinical benefit on both ACR20 responses and DAS28-CRP. Active, not recruiting --> Completed
- | leramistat (MBS2320) / Istesso, J&J
Trial completion date: Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 6, 2019
P2a, N=108, Active, not recruiting, Sponsor: Modern Biosciences plc
Active, not recruiting --> Completed Trial completion date: Dec 2018 --> Jun 2019
- | leramistat (MBS2320) / Istesso, J&J
Enrollment closed, Trial primary completion date: Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 16, 2018
P2a, N=108, Active, not recruiting, Sponsor: Modern Biosciences plc
Trial completion date: Dec 2018 --> Jun 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2018 --> Nov 2018
- |||| leramistat (MBS2320) / Istesso, J&J
Enrollment open: Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Aug 30, 2017
P2a, N=108, Recruiting, Sponsor: Modern Biosciences plc
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2018 --> Nov 2018 Not yet recruiting --> Recruiting
- ||||| leramistat (MBS2320) / Istesso, J&J
New P2a trial: Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 3, 2017
P2a, N=108, Not yet recruiting, Sponsor: Modern Biosciences plc
- ||| leramistat (MBS2320) / Istesso, J&J
Trial completion: Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 28, 2017
P1, N=105, Completed, Sponsor: Modern Biosciences plc
Not yet recruiting --> Recruiting Recruiting --> Completed
- || leramistat (MBS2320) / Istesso, J&J
Trial primary completion date: Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 14, 2016
P1, N=108, Recruiting, Sponsor: Modern Biosciences plc
Recruiting --> Completed Trial primary completion date: Dec 2016 --> Mar 2017
- ||| leramistat (MBS2320) / Istesso, J&J
Enrollment open: Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 30, 2015
P1, N=108, Recruiting, Sponsor: Modern Biosciences plc
Trial primary completion date: Dec 2016 --> Mar 2017 Not yet recruiting --> Recruiting
- leramistat (MBS2320) / Istesso, J&J
New P1 trial: Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 25, 2015
P1, N=108, Not yet recruiting, Sponsor: Modern Biosciences plc